Revance Therapeutics (NASDAQ:RVNC) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS


Share on StockTwits

Revance Therapeutics (NASDAQ:RVNC) released its earnings results on Sunday. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.25) by $0.01, MarketWatch Earnings reports. Revance Therapeutics had a negative return on equity of 85.72% and a negative net margin of 5,818.87%.

Shares of RVNC traded down $1.10 during trading hours on Tuesday, hitting $25.86. The stock had a trading volume of 45,639 shares, compared to its average volume of 425,713. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.07 and a quick ratio of 7.01. The firm has a 50 day simple moving average of $28.31 and a 200-day simple moving average of $26.92. The firm has a market capitalization of $1.72 billion, a P/E ratio of -5.70 and a beta of 1.42. Revance Therapeutics has a 1-year low of $11.78 and a 1-year high of $34.62.

In other news, insider Aubrey Rankin sold 33,119 shares of the firm’s stock in a transaction dated Monday, November 30th. The stock was sold at an average price of $23.85, for a total value of $789,888.15. Following the completion of the sale, the insider now directly owns 67,871 shares in the company, valued at approximately $1,618,723.35. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 4.80% of the company’s stock.

Several research firms recently issued reports on RVNC. Mizuho upped their target price on Revance Therapeutics from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Tuesday. Barclays boosted their price target on Revance Therapeutics from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Monday, October 26th. HC Wainwright boosted their price target on Revance Therapeutics from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday. Needham & Company LLC upped their target price on Revance Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, January 8th. Finally, Zacks Investment Research cut Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, February 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $32.88.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine.

Further Reading: How interest rates affect municipal bond prices

Earnings History for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.